Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18923023
Nishi A, et al. (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28, 10460-71 18923023
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T34-p - DARPP-32 (mouse)
Modsite: MIRRRRPtPAMLFRV SwissProt Entrez-Gene
Orthologous residues
DARPP‑32 (human): T34‑p, DARPP‑32 iso2 (human): , DARPP‑32 (mouse): T34‑p, DARPP‑32 (rat): T34‑p, DARPP‑32 (cow): T34‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'brain, striatum'
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
papaverine increase
SCH_23390 papaverine inhibit treatment-induced increase
ZM241385 papaverine inhibit treatment-induced increase
ODQ papaverine no effect upon treatment-induced increase
quinpirole papaverine inhibit treatment-induced increase
raclopride papaverine no effect upon treatment-induced increase
CGS_21680 increase
rolipram CGS_21680 augment treatment-induced increase
SKF81297 increase
rolipram SKF81297 inhibit treatment-induced increase
rolipram no change compared to control
CGS_21680 increase slight increase
SKF81297 increase slight increase
papaverine increase
CGS_21680 papaverine augment treatment-induced increase
SKF81297 papaverine augment treatment-induced increase

T183-p - ERK2 (mouse)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'brain, striatum'
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
papaverine increase
rolipram no change compared to control

Y185-p - ERK2 (mouse)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'brain, striatum'
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
papaverine increase
rolipram no change compared to control

S863-p - GluR1 (mouse)
Modsite: TSTLPRNsGAGASGG SwissProt Entrez-Gene
Orthologous residues
GluR1 (human): S863‑p, GluR1 iso6 (human): S873‑p, GluR1 (mouse): S863‑p, GluR1 (rat): S863‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'brain, striatum'
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
haloperidol increase small increase
papaverine haloperidol augment treatment-induced increase
rolipram haloperidol augment treatment-induced increase
papaverine no change compared to control striatum in vivo
rolipram no change compared to control

S9-p - SYN1 (mouse)
Modsite: NYLRRRLsDSNFMAN SwissProt Entrez-Gene
Orthologous residues
SYN1 (human): S9‑p, SYN1 iso2 (human): S9‑p, SYN1 (mouse): S9‑p, SYN1 iso1 (mouse): S9‑p, SYN1 iso3 (mouse): S9‑p, SYN1 (rat): S9‑p, SYN1 (cow): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'brain, striatum'
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
papaverine increase
rolipram increase

S40-p - TH (mouse)
Modsite: RFIGRRQsLIEDARK SwissProt Entrez-Gene
Orthologous residues
TH (human): S71‑p, TH iso2 (human): S67‑p, TH iso3 (human): S40‑p, TH iso4 (human): S44‑p, TH (mouse): S40‑p, TH (rat): S40‑p, TH (cow): S40‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'brain, striatum'
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
papaverine increase
rolipram increase
haloperidol increase
papaverine haloperidol no effect upon treatment-induced increase
rolipram haloperidol augment treatment-induced increase
papaverine no change compared to control
rolipram no change compared to control